NRGV reported earnings on August 11 and the initial reaction was a 7% gain — but the more telling story is what shorts did around that print, reversing a multi-week retreat and rebuilding positions faster than the stock could rally.
The previous note, published ahead of the August 11 earnings, documented bears steadily trimming from above 33 million shares in mid-July to just under 29 million. That trend has now reversed. Short interest climbed back to 18.3% of the free float — 30.8 million shares — up roughly 1.5% on the week and 6% on the month. The single sharpest move came Tuesday, August 11, when short shares jumped by 1.36 million in one session. Bears who covered into the earnings print appear to have quickly rebuilt once the post-announcement relief rally looked limited. Borrow conditions reflect that renewed demand: availability tightened sharply, from around 37% last Friday to just 14% as of Tuesday — roughly one share available for every seven already lent out. Cost to borrow is rising too, up 20% on the week to 1.29%, its highest level in a month. The direction across all three lending-market indicators is now the same — tighter, more expensive, and less room left.
Options positioning tells a similar cautious story, but with a call-heavy twist. The put/call ratio hit 0.27, more than two standard deviations above its 20-day mean of 0.23 — still a calls-dominated market, but the defensive tilt has grown noticeably in recent sessions. This is the highest PCR reading of the past several months, suggesting options traders hedged more aggressively into the print. The ORTEX short score has held steady near 74.5, ranking NRGV in the bottom 2nd percentile of stocks on the short score rank — meaning the lending and positioning data collectively classify this as one of the more heavily pressured names in the market.
The Street's read on NRGV shifted materially on earnings day. Roth Capital raised its price target from $5 to $7 while reiterating Buy, and Cantor Fitzgerald held at $7 Overweight — both fresh as of August 12. Citigroup upgraded to Buy from Neutral in late July, though it trimmed its target slightly to $5. Goldman Sachs remains the dissenting voice, maintaining Sell with a $2 target — well below the current $3.58 price. The consensus mean target sits at $5.93, implying roughly 66% upside from current levels, but the Goldman outlier anchors the bear case firmly. Factor scores add some colour to the bull argument: EPS surprise ranks in the 91st percentile, and the analyst recommendation differential scores in the 93rd — reflecting genuine conviction from the Buy-side coverage even as the lone Sell drags the headline average down.
Institutional flows add an interesting layer. BlackRock added 9 million shares in the most recently reported period, a substantial build for a stock of this size. CEO Robert Piconi also added to his stake — though the insider picture is complicated by concurrent sales from the same executives. The CFO sold $265,000 worth of stock in early July. The COO sold in late June. Piconi himself sold in June and bought a small amount in March. Net insider activity over 90 days is slightly positive in share terms, but the selling at higher prices through June, while the stock has since pulled back, reduces the signal quality.
What to watch next is straightforward: whether the short rebuild around earnings resolves as a sustained push higher or stalls as bears use the tight availability to lean on any further bounce — the November earnings date is the next hard catalyst, and availability trends between now and then will indicate whether the squeeze risk that hovered over the August print remains live.
See the live data behind this article on ORTEX.
Open NRGV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
